ALS is a rapidly progressive, fatal neurodegenerative condition characterised by muscle weakness, atrophy, and spasticity. Current ALS treatment options include glutamate antagonists, free radical scavengers, antisense oligonucleotides, and apoptotic regulators that all manage the disease, but are not curative. The high failure rate in ALS clinical trials is often attributed to the disease’s unclear etiology and complex pathophysiology